Like what you hear? Download Curie, your go-to app for curated healthcare podcasts.

In this episode of Curie, we explore why healthcare professionals are flocking to Bluesky—a social media platform offering a refreshing alternative to X. Discover the features driving this migration, the challenges of digital networking, and what it means for the future of professional collaboration.

The ASH 2024 wrap-up is here! We’re spotlighting the most impactful developments, including menin inhibitors redefining AML treatment, promising gene-editing therapies for sickle cell disease, and next-gen CAR-T advances. Don’t miss this final episode!

Like what you hear? Download Curie from the App store for personalized insights.

The shocking death of UnitedHealthcare CEO Brian Thompson has sparked outrage and reflection on the state of American healthcare. In this episode, Curie host Matt investigates the deeper questions: Why do so many Americans feel betrayed by their insurers? How do profit-driven motives in healthcare create systemic failures?

We break down the numbers, including UnitedHealthcare’s industry-high claim denial rate of 32%, and explore how cost-saving measures may cross ethical boundaries. With stories of real patients caught in the crossfire of a flawed system, this episode is a compelling look at the intersection of healthcare and morality.

If you found this episode thought-provoking, download Curie today for more in-depth discussions on the stories shaping healthcare. Don’t miss our critical conversations.

On Day 4 of ASH 2024, explore the remarkable 96% disease-free survival with Blincyto in pediatric ALL, deep responses with Epcoritamab in relapsed CLL, and the promise of a next-gen BCL2 inhibitor in a potent CLL combination. Tune in for transformative insights! Like what you hear? Download Curie from the App store for personalized insights.

Day 3 of ASH 2024 revealed groundbreaking findings: a 97% complete response rate for zilovertamab vedotin in diffuse large B-cell lymphoma, new insights into zanubrutinib’s efficacy in chronic lymphocytic leukemia, and promising survival data for belantamab mafodotin in multiple myeloma. Like what you hear? Download Curie from the App Store for more personalized healthcare content.

On Day 2 of ASH 2024, we explore breakthroughs in treating high-risk smoldering multiple myeloma, advancements in chronic lymphocytic leukemia therapies, and a revealing study on leukemia risk in Ground Zero first responders. Stay updated with insights that are reshaping hematology practice.

Love what you hear? Download the Curie app for daily updates and bonus episodes tailored for oncology professionals.

Day 1 of ASH 2024 brought exciting advancements in hematology. In this episode, we explore highlights from pivotal trials, including etavopivat’s impact on sickle cell disease, rilzabrutinib’s rapid platelet response in ITP, and hydroxyurea’s benefits for HbSC patients. Hosted by Matt, this podcast offers clear insights into the research shaping tomorrow’s treatments.

Love what you hear? Download the Curie app for daily updates and bonus episodes tailored for oncology professionals.

Robert F. Kennedy Jr.’s nomination as Secretary of Health and Human Services has sparked intense debate. In this episode, we explore his controversial stances on vaccines, fluoride, and public health, his ambitious reform agenda, and the potential implications for America’s health policy.

Enjoyed the episode? Download the Curie app here to personalize your listening experience. Get two exclusive episodes every week—on Mondays and Thursdays—plus bonus content available only on the app!

New episodes drop on Spotify and Apple Podcasts every Thursday.